Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Standard
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. / Tejpar, Sabine; Celik, Ilhan; Schlichting, Michael; Sartorius, Ute; Bokemeyer, Carsten; Eric, Van Cutsem.
in: J CLIN ONCOL, Jahrgang 30, Nr. 29, 29, 2012, S. 3570-3577.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
AU - Tejpar, Sabine
AU - Celik, Ilhan
AU - Schlichting, Michael
AU - Sartorius, Ute
AU - Bokemeyer, Carsten
AU - Eric, Van Cutsem
PY - 2012
Y1 - 2012
N2 - We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment.
AB - We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Young Adult
KW - Multivariate Analysis
KW - Treatment Outcome
KW - Risk Assessment
KW - Survival Analysis
KW - Follow-Up Studies
KW - Disease-Free Survival
KW - Proportional Hazards Models
KW - Mutation
KW - Gene Expression Regulation, Neoplastic
KW - Neoplasm Staging
KW - Neoplasm Metastasis
KW - Likelihood Functions
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Antibodies, Monoclonal/therapeutic use
KW - Proto-Oncogene Proteins/genetics
KW - ras Proteins/genetics
KW - Neoplasm Invasiveness/pathology
KW - Colorectal Neoplasms/drug therapy/genetics/mortality/pathology
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Young Adult
KW - Multivariate Analysis
KW - Treatment Outcome
KW - Risk Assessment
KW - Survival Analysis
KW - Follow-Up Studies
KW - Disease-Free Survival
KW - Proportional Hazards Models
KW - Mutation
KW - Gene Expression Regulation, Neoplastic
KW - Neoplasm Staging
KW - Neoplasm Metastasis
KW - Likelihood Functions
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Antibodies, Monoclonal/therapeutic use
KW - Proto-Oncogene Proteins/genetics
KW - ras Proteins/genetics
KW - Neoplasm Invasiveness/pathology
KW - Colorectal Neoplasms/drug therapy/genetics/mortality/pathology
M3 - SCORING: Journal article
VL - 30
SP - 3570
EP - 3577
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 29
M1 - 29
ER -